Entrectinib Data Highlighted as FDA Weighs Approval for ROS1+ NSCLC

April 11, 2019 – Patients with ROS1-positive non–small cell lung cancer (NSCLC) showed high response rates and durable responses following treatment with entrectinib, according to findings from a pooled analysis of 3 studies presented at the 2019 European Lung Cancer Congress. Entrectinib demonstrated systemic efficacy with 77.4% of patients in the overall population showing a response. Strong intracranial activity was also demonstrated in a cohort of patients … (leggi tutto)